Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

UCF research opens a new exploratory path for Alzheimer's disease

Despite a massive global research effort, many basics of Alzheimer's disease onset remain elusive. This has hampered development of treatments effective during the earliest stages of the disease, when prevention is most likely.

9 Jan 2010

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

John C. Lechleiter, PhD, Chairman, President & CEO, Eli Lilly and Company, will deliver a keynote address, "Lifespans and Livelihoods: The Human Dimensions of Medical Innovation," to TOWN HALL Los Angeles on Thursday, January 14, 2010 at the Millennium Biltmore Hotel.

8 Jan 2010

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Forgot where you put your car keys? Having trouble recalling your colleague's name? If so, this may be a symptom of subjective cognitive impairment (SCI), the earliest sign of cognitive decline marked by situations such as when a person recognizes they can't remember a name like they used to or where they recently placed important objects the way they used to.

8 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain.

8 Jan 2010

Researchers seek to defeat Alzheimer's disease by modifying mice's immune system

Using laboratory mice that had been bred to have brain changes similar to Alzheimer's disease, scientists were able to reduce two characteristic features of the disease by modifying the mice's immune systems with a special peptide (MOG45D) related to the myelin sheath that insulates nerve cells and nerve fibers. As a result, anti-inflammatory cells were recruited from the blood into the brain, dampening the local inflammatory response.

7 Jan 2010

New wireless monitoring device prevents and detects mobility problems among elderly

Falls are the main cause of injuries among elderly people, but until now doctors have had few ways of effectively monitoring and counteracting mobility problems among patients. Work by European researchers is set to change that.

7 Jan 2010

Nutrient mix shows potential to improve memory in Alzheimer's patients

In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.

7 Jan 2010

Dakim expands distribution of dementia-fighting Dakim BrainFitness System to Canada

Dakim, Inc. announced today that it is expanding distribution of its dementia-fighting Dakim® BrainFitness(TM) System to Canada through a partnership with Tock Tick, Inc. Dakim's touch screen-based system is the #1 cognitive stimulation product in U.S. senior living communities, providing an entertaining and easy-to-use brain workout that is specifically designed to help seniors maintain their brain health.

7 Jan 2010

Fountainview offers innovative amenities for independent seniors

Fountainview at Eisenberg Village, a Continuing Care Retirement Community (CCRC), will officially open its doors for Charter Members to begin moving in on Monday, February 15, 2010.

7 Jan 2010

Diffusion tensor imaging detects signs of Alzheimer's disease

A new type of brain scan, called diffusion tensor imaging (DTI), appears to be better at detecting whether a person with memory loss might have brain changes of Alzheimer's disease, according to a new study published in the January 6, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

7 Jan 2010

New evidence suggests long-term exposure to cell phone signals may protect against Alzheimer's disease

The millions of people who spend hours every day on a cell phone may have a new excuse for yakking. A surprising new study in mice provides the first evidence that long-term exposure to electromagnetic waves associated with cell phone use may actually protect against, and even reverse, Alzheimer's disease.

6 Jan 2010

University of Montreal expands treatment capacity with EON Reality's simulations system

EON Reality, the world's leading interactive 3D software provider, today announced that the Visual Psychophysics and Perception Laboratory at the University of Montreal expands their treatment capacity with a fully immersive environment from EON Reality. A new simulations system for rehabilitation and training of athletic performance, developed by Professor Jocelyn Faubert's team, will be immersed within the EON Icube, a technology that allows virtual training in a natural and realistic environment.

6 Jan 2010

SAVE THE PATIENT to host community show to help seniors navigate long-term care issues

Senior citizens and their families often feel overwhelmed when dealing with health issues. Finding the right care services to fit their needs can be a daunting task -- but need not be. SAVE THE PATIENT is hosting another community show to bring insights, ideas and understandable answers to the Chicago public.

6 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Study identifies novel factor that causes Alzheimer's disease

Inheritance of an extra copy of the gene- β -amyloid precursor protein, APP, in individuals with Down syndrome leads to the inevitable development of early onset Alzheimer's disease, known to be linked to the deposition of Amyloid β peptide or Aβ in the brain.

5 Jan 2010

FDA approves generic donepezil hydrochloride orally disintegrating tablets

The U.S. Food and Drug Administration approved the first generic versions of Aricept (donepezil hydrochloride) orally disintegrating tablets on Dec. 11. Donepezil hydrochloride is indicated for the treatment of dementia related to Alzheimer's disease.

5 Jan 2010

Rising prevalence of dementia will cripple Canadian families, the health care system and economy

A report released by the Alzheimer Society today to mark Alzheimer Awareness Month reveals alarming new statistics about the projected economic and social costs of dementia in Canada. Rising Tide: The Impact of Dementia on Canadian Society, says that, if nothing changes the prevalence of dementia will more than double in 30 years, with the costs increasing ten-fold.

4 Jan 2010

Aegis Living provides guidance on senior living communities

It's a fact: each and every January senior living communities see an increase in inquiries from concerned family members looking for help and answers as to how to best care for an aging loved one that needs assistance

4 Jan 2010

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

3 Jan 2010

Alzheimer's Disease News and Research

Further Reading

UCF research opens a new exploratory path for Alzheimer's disease

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

University Hospitals Case Medical Center conducts Phase 2 clinical trial of gene therapy for AD

Researchers seek to defeat Alzheimer's disease by modifying mice's immune system

New wireless monitoring device prevents and detects mobility problems among elderly

Nutrient mix shows potential to improve memory in Alzheimer's patients

Dakim expands distribution of dementia-fighting Dakim BrainFitness System to Canada

Fountainview offers innovative amenities for independent seniors

Diffusion tensor imaging detects signs of Alzheimer's disease

New evidence suggests long-term exposure to cell phone signals may protect against Alzheimer's disease

University of Montreal expands treatment capacity with EON Reality's simulations system

SAVE THE PATIENT to host community show to help seniors navigate long-term care issues

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Study identifies novel factor that causes Alzheimer's disease

FDA approves generic donepezil hydrochloride orally disintegrating tablets

Rising prevalence of dementia will cripple Canadian families, the health care system and economy

Aegis Living provides guidance on senior living communities

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

Aneuro: An Overview of Neuroscience Research eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News